拨康视云™
Cloudbreak Pharma

CLOUDBREAK PHARMA INC.

撥康視雲製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2592)

VOLUNTARY ANNOUNCEMENT

BUSINESS UPDATE IN RELATION TO SUCCESSFUL PATENT APPLICATIONS IN JAPAN AND EUROPE

This announcement is made by Cloudbreak Pharma Inc. (the "**Company**"; together with its subsidiaries, the "**Group**") on a voluntary basis for the purpose of keeping the shareholders and potential investors of the Company informed of the latest business development of the Group.

SUCCESSFUL PATENT APPLICATIONS IN JAPAN AND EUROPE

The board of directors of the Company (the "**Board**") is pleased to announce that ADS Therapeutics LLC ("**ADS USA**"), a wholly-owned subsidiary of the Company registered under the laws of Delaware, the United States of America (the "**USA**"), has successfully obtained the grants of the following patents in respect of CBT-009, one of the core products (as defined in Chapter 18A of the Rules Governing the Listing of Securities on the Stock Exchange) (each a "**Core Product**") of the Group:

(a) a patent granted by the Japan Patent Office (the "**JPO**") under the certificate of patent issued by the JPO dated 25 September 2025 (Japanese Patent Number: 7749020) (the "**Japanese Patent**") and published in the Official Gazette of the JPO on 3 October 2025, directed to various topical ophthalmological compositions, including a non-aqueous topical ophthalmological composition comprising certain amounts of atropine, a medium chain triglyceride liquid vehicle, and a selected semi-fluorinated alkane compound, as well as uses thereof, such as in slowing myopia progression; and

(b) a patent granted by the European Patent Office (the "**EPO**") on 26 November 2025 (European Patent Number: 4225284) (the "**European Patent**"; together with the Japanese Patent, the "**Patents**") and published in the European Patent Bulletin 2025/48 of the EPO on the same date, directed to various topical ophthalmological compositions, including a topical ophthalmological composition comprising atropine and a semi-fluorinated alkane as a liquid vehicle, for treating ocular diseases such as myopia.

The above-mentioned Patents are the most recent additions to the Group's CBT-009 patent portfolio as disclosed by the Company in its prospectus dated 24 June 2025 and in the interim report of the Group for the six months ended 30 June 2025.

CBT-009, a Core Product of the Group, is a novel ophthalmic formulation of atropine indicated for the treatment of juvenile myopia in children and adolescents aged 5 to 19 years. It is designed as a non-aqueous formulation to improve stability, safety, and patient tolerability compared to existing aqueous-based formulations. Pre-clinical studies for CBT-009 were commenced in the People's Republic of China (the "**PRC**") and the USA in 2021 and 2022, respectively. The combined phase 1 and phase 2 clinical trials for CBT-009 were completed in Australia in January 2023, demonstrating favourable safety and efficacy profiles. In September 2024, after a six-month ocular toxicity study, the Group received the approval letter of the Food and Drug Administration of the USA stating that it had no objection to the Group proceeding with phase 3 clinical trial. The Group also commenced the toxicity study on juvenile animals in the PRC in February 2025 and is actively preparing for the commencement of phase 3 clinical trials for CBT-009 in due course. The Company expects that CBT-009 will outperform its atropine-based competitors and the other current treatment methods in various aspects, including drug stability, safety, patient tolerability, and length of shelf life and become a best-in-class product, once approved.

The Company considers the success of the applications for the Patents to be a significant milestone in the development of CBT-009, which will enhance CBT-009's global reach and facilitate the progress of its commercialisation. It is anticipated that the Group will be able to initiate collaboration with major pharmaceutical corporations to establish licensing arrangements for the manufacture, development and distribution of CBT-009 in both Japan and Europe, which represent key premium markets for CBT-009. Such collaboration and licensing arrangements are expected to enhance and accelerate CBT-009's global commercialisation potential. The Company will make further announcement(s) to keep the shareholders and potential investors of the Company informed of the latest developments in relation to the Group's business as and when appropriate.

Warning Statement: There is no guarantee that CBT-009 or any other Core Product of the Group will ultimately be successfully developed, launched or marketed.

Shareholders and potential investors of the Company should exercise caution and due care when dealing in the shares of the Company.

By order of the Board
Cloudbreak Pharma Inc.
Dr. NI Jinsong
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 27 November 2025

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Ni Jinsong, Mr. Dinh Son Van and Dr. Yang Rong as executive directors; (ii) Dr. Li Jun Zhi, Mr. Cao Xu and Mr. Xia Zhidong as non-executive directors; and (iii) Mr. Lai Hin Wing Henry Stephen, Ms. Nie Sijiang and Mr. Ma Yiu Ho Peter as independent non-executive directors.

* *For identification purpose only*